[go: up one dir, main page]

MX350565B - Composiciones farmaceuticas. - Google Patents

Composiciones farmaceuticas.

Info

Publication number
MX350565B
MX350565B MX2013005813A MX2013005813A MX350565B MX 350565 B MX350565 B MX 350565B MX 2013005813 A MX2013005813 A MX 2013005813A MX 2013005813 A MX2013005813 A MX 2013005813A MX 350565 B MX350565 B MX 350565B
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
administration
prevention
risk
reduction
Prior art date
Application number
MX2013005813A
Other languages
English (en)
Other versions
MX2013005813A (es
Inventor
Danping Li
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of MX2013005813A publication Critical patent/MX2013005813A/es
Publication of MX350565B publication Critical patent/MX350565B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se relaciona con composiciones farmacéuticas útiles para la administración para el tratamiento, prevención o reducción del riesgo de infecciones microbianas.
MX2013005813A 2010-11-24 2011-11-21 Composiciones farmaceuticas. MX350565B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41680710P 2010-11-24 2010-11-24
PCT/US2011/061643 WO2012071324A2 (en) 2010-11-24 2011-11-21 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
MX2013005813A MX2013005813A (es) 2013-09-13
MX350565B true MX350565B (es) 2017-09-11

Family

ID=46146374

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005813A MX350565B (es) 2010-11-24 2011-11-21 Composiciones farmaceuticas.

Country Status (21)

Country Link
US (2) US20140088164A1 (es)
EP (1) EP2642996B1 (es)
JP (2) JP6370550B2 (es)
KR (1) KR101944124B1 (es)
CN (1) CN103391778B (es)
AU (1) AU2011332031B2 (es)
BR (1) BR112013012833A8 (es)
CA (1) CA2818249C (es)
EA (1) EA027791B1 (es)
ES (1) ES2836809T3 (es)
HU (1) HUE052801T2 (es)
IL (1) IL226378A0 (es)
MX (1) MX350565B (es)
MY (2) MY182136A (es)
NZ (1) NZ610638A (es)
PH (1) PH12013501069A1 (es)
PT (1) PT2642996T (es)
SG (2) SG10201509530YA (es)
UA (1) UA113722C2 (es)
WO (1) WO2012071324A2 (es)
ZA (1) ZA201303732B (es)

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5895663A (en) 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
US6451345B1 (en) * 2000-01-20 2002-09-17 Eurand Pharmaceuticals Ltd. Functional coating of linezolid microcapsules for taste-masking and associated formulation for oral administration
UY26615A1 (es) 2000-03-16 2001-10-25 Pfizer Prod Inc Inhibidor de la glucogeno fosforilasa.
AU4324301A (en) * 2000-03-22 2001-10-03 Upjohn Co Oxazolidinone tablet formulation
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
MXPA02012045A (es) 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Nuevos derivados de oxazolidinona y proceso para su preparacion.
AU2001267011B2 (en) * 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2002241268A (ja) * 2000-12-11 2002-08-28 Takeda Chem Ind Ltd 水溶解性が改善された医薬組成物
PL362979A1 (en) 2000-12-11 2004-11-02 Takeda Chemical Industries, Ltd. Medicinal compositions improved in solublity in water
MXPA05013132A (es) * 2003-06-03 2006-05-25 Rib X Pharmaceuticals Inc Compuestos heterociclicos de biarilo y metodos de produccion y su uso.
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
TW200534879A (en) * 2004-03-25 2005-11-01 Bristol Myers Squibb Co Coated tablet formulation and method
AU2006242535B2 (en) * 2005-04-29 2012-08-09 Merck Sharp & Dohme Corp. Therapeutic compositions
US20070026073A1 (en) 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
US20070026072A1 (en) * 2005-07-28 2007-02-01 Stephen Olsen Benzoquinones of enhanced bioavailability
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
WO2007092642A2 (en) * 2006-02-09 2007-08-16 Merck & Co., Inc. Polymer formulations of cetp inhibitors
AU2007283196A1 (en) * 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
EA022765B1 (ru) * 2009-10-13 2016-02-29 Мелинта Терапьютикс, Инк. Фармацевтическая композиция
US9040033B2 (en) * 2010-06-14 2015-05-26 Dow Global Technologies Llc Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution
CA2816077C (en) * 2010-11-01 2021-08-10 Rib-X Pharmaceuticals, Inc. Antimicrobial compositions comprising an emulsifier and dissolution aid

Also Published As

Publication number Publication date
EA201390764A1 (ru) 2013-09-30
CN103391778B (zh) 2016-04-20
MY171941A (en) 2019-11-08
KR20140033314A (ko) 2014-03-18
JP2013543893A (ja) 2013-12-09
WO2012071324A2 (en) 2012-05-31
NZ610638A (en) 2015-05-29
WO2012071324A3 (en) 2012-08-16
CN103391778A (zh) 2013-11-13
SG10201509530YA (en) 2015-12-30
AU2011332031A1 (en) 2013-06-06
MY182136A (en) 2021-01-18
CA2818249A1 (en) 2012-05-31
CA2818249C (en) 2021-04-13
BR112013012833A8 (pt) 2018-01-02
PT2642996T (pt) 2020-12-30
US20160374995A1 (en) 2016-12-29
MX2013005813A (es) 2013-09-13
EP2642996A2 (en) 2013-10-02
IL226378A0 (en) 2013-07-31
BR112013012833A2 (pt) 2016-08-23
ZA201303732B (en) 2018-12-19
US20140088164A1 (en) 2014-03-27
US10300046B2 (en) 2019-05-28
JP6370550B2 (ja) 2018-08-08
HUE052801T2 (hu) 2021-05-28
EP2642996A4 (en) 2014-05-21
EA027791B1 (ru) 2017-09-29
UA113722C2 (uk) 2017-03-10
PH12013501069A1 (en) 2013-07-08
SG190354A1 (en) 2013-06-28
ES2836809T3 (es) 2021-06-28
JP2017081950A (ja) 2017-05-18
AU2011332031B2 (en) 2017-01-12
EP2642996B1 (en) 2020-09-23
KR101944124B1 (ko) 2019-01-30

Similar Documents

Publication Publication Date Title
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
BR112014021531A8 (pt) composto, composição farmacêutica e usos dos mesmos
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX2015015506A (es) Peptidos antimicrobianos.
PH12015501609A1 (en) Phenicol antibacterials
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
PH12016501988A1 (en) Antibacterial compounds
MX376183B (es) Composiciones para el tratamiento de rosacea.
BR112016024235A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112015016033A2 (pt) composições e métodos para tratamento de infecções por bactérias
UA105260C2 (ru) Фармацевтическая композиция для приготовления инфузионных растворов антимикробных препаратов, способ ее получения (варианты)
UA113151C2 (xx) Застосування композиції, що містить антимікробний поліпептид, у виробництві лікарського засобу
IN2014DN03010A (es)
EA201270547A1 (ru) Фармацевтическая композиция
UA117672C2 (uk) Антибактеріальні сполуки
MX350565B (es) Composiciones farmaceuticas.
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
MX360040B (es) Nuevo agente antibacteriano derivado de florfenicol unido a sulfoximina y el uso del mismo en el tratamiento de infecciones bacterianas en ganado vacuno.
IN2014KN02584A (es)
BR112016029761A2 (pt) composições antimicrobianas com agentes efervescentes
WO2014147578A3 (en) Antibacterial compounds against drug resistant bacteria
UA108238C2 (xx) Антибактеріальна композиція

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: EISAI R&D MANAGEMENT CO., LTD.*

Owner name: HENKEL IP & HOLDING GMBH

FG Grant or registration